M Hintz1, S Nawratil2, A Schulze-Bonhage2. 1. Abteilung Prächirurgische Epilepsiediagnostik - Epilepsiezentrum, Klinik für Neurochirurgie, Universitätsklinikum Freiburg, Breisacher Str. 64, 79106, Freiburg, Deutschland. mandy.hintz@uniklinik-freiburg.de. 2. Abteilung Prächirurgische Epilepsiediagnostik - Epilepsiezentrum, Klinik für Neurochirurgie, Universitätsklinikum Freiburg, Breisacher Str. 64, 79106, Freiburg, Deutschland.
Abstract
BACKGROUND: This article describes a monocentric retrospective analysis of clinical experience with the latest antiepileptic drug perampanel with non-competitive modulation of postsynaptic AMPA receptors. MATERIAL AND METHODS: Evaluation of electronic medical charts of patients newly treated with perampanel between 2012 and 2014 at the epilepsy center of the University Hospital Freiburg regarding effectiveness and tolerability. RESULTS: A total of 85 patients (45 male, mean age 37.4 years, range 14-80 years) with therapy resistance to an average of 6 antiepileptic medications were newly treated with add-on perampanel. Of the patients 35 % experienced a relevant reduction in seizures. The most commonly reported side effects were tiredness (32.5 %), dizziness (24.5 %) and irritability (10.5 %). The dosages resulting in a significant reduction in seizures which varied between patients from 4 to 12 mg/day. Even multidrug-resistant patients who had not benefited from vagus nerve and deep brain stimulation, profited from add-on treatment with perampanel. CONCLUSION: In this cohort, even epilepsy patients who did not respond to multiple previous antiepileptic treatment profited from add-on therapy with the new mode of action of perampanel.
BACKGROUND: This article describes a monocentric retrospective analysis of clinical experience with the latest antiepileptic drug perampanel with non-competitive modulation of postsynaptic AMPA receptors. MATERIAL AND METHODS: Evaluation of electronic medical charts of patients newly treated with perampanel between 2012 and 2014 at the epilepsy center of the University Hospital Freiburg regarding effectiveness and tolerability. RESULTS: A total of 85 patients (45 male, mean age 37.4 years, range 14-80 years) with therapy resistance to an average of 6 antiepileptic medications were newly treated with add-on perampanel. Of the patients 35 % experienced a relevant reduction in seizures. The most commonly reported side effects were tiredness (32.5 %), dizziness (24.5 %) and irritability (10.5 %). The dosages resulting in a significant reduction in seizures which varied between patients from 4 to 12 mg/day. Even multidrug-resistant patients who had not benefited from vagus nerve and deep brain stimulation, profited from add-on treatment with perampanel. CONCLUSION: In this cohort, even epilepsypatients who did not respond to multiple previous antiepileptic treatment profited from add-on therapy with the new mode of action of perampanel.
Authors: G L Krauss; J M Serratosa; V Villanueva; M Endziniene; Z Hong; J French; H Yang; D Squillacote; H B Edwards; J Zhu; A Laurenza Journal: Neurology Date: 2012-04-18 Impact factor: 9.910
Authors: Jacqueline A French; Gregory L Krauss; Bernhard J Steinhoff; David Squillacote; Haichen Yang; Dinesh Kumar; Antonio Laurenza Journal: Epilepsia Date: 2012-08-20 Impact factor: 5.864
Authors: Guilherme F Silva; Mário Tanomaru-Filho; Maria I B Bernardi; Juliane M Guerreiro-Tanomaru; Paulo S Cerri Journal: Clin Oral Investig Date: 2015-02-03 Impact factor: 3.573
Authors: Bernhard J Steinhoff; Hajo Hamer; Eugen Trinka; Andreas Schulze-Bonhage; Christian Bien; Thomas Mayer; Christoph Baumgartner; Holger Lerche; Soheyl Noachtar Journal: Epilepsy Res Date: 2014-03-27 Impact factor: 3.045